Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 plus gemcitabine and nab-paclitaxel for neoadjuvant and adjuvant treatment of KRAS G12D-mutant pancreatic cancer
ChiCTR2400089937Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HRS-4642, gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Ruijin Hospital. Primary endpoints: Safety and R0 resection rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
HRS-4642gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400089937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089937.